CTXR vs. RNAC, KPTI, SCTL, GLYC, ACET, RPTX, PDSB, AMLX, IMUX, and ABEO
Should you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include Cartesian Therapeutics (RNAC), Karyopharm Therapeutics (KPTI), Societal CDMO (SCTL), GlycoMimetics (GLYC), Adicet Bio (ACET), Repare Therapeutics (RPTX), PDS Biotechnology (PDSB), Amylyx Pharmaceuticals (AMLX), Immunic (IMUX), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical preparations" industry.
Cartesian Therapeutics (NASDAQ:RNAC) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings, valuation and community ranking.
Citius Pharmaceuticals has lower revenue, but higher earnings than Cartesian Therapeutics.
Citius Pharmaceuticals has a net margin of 0.00% compared to Citius Pharmaceuticals' net margin of -983.93%. Cartesian Therapeutics' return on equity of -41.63% beat Citius Pharmaceuticals' return on equity.
Cartesian Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500.
In the previous week, Cartesian Therapeutics had 21 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 25 mentions for Cartesian Therapeutics and 4 mentions for Citius Pharmaceuticals. Cartesian Therapeutics' average media sentiment score of 0.93 beat Citius Pharmaceuticals' score of 0.39 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media.
Cartesian Therapeutics currently has a consensus price target of $45.00, suggesting a potential upside of 112.56%. Citius Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 475.79%. Given Cartesian Therapeutics' higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Cartesian Therapeutics.
Citius Pharmaceuticals received 198 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cartesian Therapeutics an outperform vote while only 62.05% of users gave Citius Pharmaceuticals an outperform vote.
87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 31.2% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 15.0% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Cartesian Therapeutics and Citius Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.
Get Citius Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Citius Pharmaceuticals Competitors List
Related Companies and Tools
